Table 1.
Effects of Different Ratios and Doses of β-Glycosphingolipids on Liver Enzyme Activity in the Con A Hepatitis Model (Percentage of Control)
| Group | Treatment | ALT (%) | AST (%) |
|---|---|---|---|
| A | PBS | 100 | 100 |
| B | GC 0.5 mg/mouse | 81.63 | 80.46 |
| C | LC 0.5 mg/mouse | 77.54 | 78.06 |
| D | IGL (0.25 + 0.25) mg/mouse | 63.32 | 81.23 |
| E | GC 1.5 mg/mouse | 58.40 | 61.00 |
| F | LC 1.5 mg/mouse | 62.11 | 65.29 |
| G | IGL 0.75 + 0.75 mg/mouse | 47.17 | 48.42 |
| H | GC 15 mg/mouse | 65.58 | 68.01 |
| I | LC 15 mg/mouse | 66.54 | 64.14 |
| J | IGL 7.5 + .7.5 mg/mouse | 83.62 | 68.73 |
| K | GC 75 mg/mouse | 41.78 | 45.74 |
| L | LC 75 mg/mouse | 64.00 | 65.28 |
| M | IGL 37.5 + 37.5 mg/mouse | 55.22 | 55.35 |